Lincoln Pharmaceuticals Ltd (IN:LINCOLN)
:LINCOLN
Want to see IN:LINCOLN full AI Analyst Report?
LINCOLN Stock Chart & Stats
₹496.60
-₹14.55(-1.74%)
At close: 4:00 PM EST
₹496.60
-₹14.55(-1.74%)
Day’s Range― - ―
52-Week Range₹439.95 - ₹750.00
Previous CloseN/A
Volume57.32K
Average Volume (3M)1.66K
Market Cap
₹14.64B
Enterprise Value₹14.48B
Total Cash (Recent Filing)₹2.32B
Total Debt (Recent Filing)₹668.00K
Price to Earnings (P/E)8.5
Beta1.08
Next Earnings
May 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.37%
Share Statistics
EPS (TTM)39.95
Shares Outstanding20,029,728
10 Day Avg. Volume3,133
30 Day Avg. Volume1,664
Financial Highlights & Ratios
PEG Ratio-1.14
Price to Book (P/B)1.65
Price to Sales (P/S)1.77
P/FCF Ratio14.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)72
Revenue Forecast (FY)₹8.82B
Bulls Say, Bears Say
Bulls Say
Near‑zero Debt / Strong Balance SheetLincoln's virtually debt‑free balance sheet and near‑zero debt‑to‑equity profile provide durable financial flexibility. This reduces solvency risk, enables opportunistic capex, R&D or M&A funding without leverage, and supports resilience through industry cycles while preserving investment optionality.
Rebounded Free Cash FlowA sharp rebound in free cash flow increases internal funding capacity for product development, facility investment and shareholder returns. With FCF covering ~79% of net income in 2025, the company can fund growth and absorb shocks without relying on external financing, improving long‑term sustainability.
Steady Revenue Growth & High Gross MarginsConsistent top‑line expansion combined with gross margins above 50% indicates durable product economics and pricing power in finished formulations. High gross margins provide a cushion against input cost volatility and support sustained operating profitability across therapeutic segments and export channels.
Bears Say
Margin Compression In 2025Material margin erosion between 2024 and 2025 signals persistent cost pressures or weaker pricing that can impair long‑term earnings power. If sustained, lower margins reduce reinvestment capacity and ROE, making future growth more dependent on volume expansion or structural margin recovery rather than operational leverage.
Cash Conversion VariabilityOperating cash flow consistently trailing net income suggests working‑capital swings and earnings quality variability. Prolonged cash conversion weakness can strain liquidity, limit the benefits of a low‑debt profile, and force reliance on slower FCF realization or non‑operational financing to bridge cyclical needs.
Negative EPS Growth Recent PeriodReported negative EPS growth reflects near‑term earnings pressure and aligns with margin contraction. Sustained EPS declines undermine return metrics and could indicate slower profit recovery from rising costs or product mix shifts, limiting the company's ability to steadily improve shareholder returns over the medium term.
Lincoln Pharmaceuticals Ltd News
LINCOLN FAQ
What was Lincoln Pharmaceuticals Ltd’s price range in the past 12 months?
Lincoln Pharmaceuticals Ltd lowest stock price was ₹439.95 and its highest was ₹750.00 in the past 12 months.
What is Lincoln Pharmaceuticals Ltd’s market cap?
Lincoln Pharmaceuticals Ltd’s market cap is ₹14.64B.
When is Lincoln Pharmaceuticals Ltd’s upcoming earnings report date?
Lincoln Pharmaceuticals Ltd’s upcoming earnings report date is May 28, 2026 which is in 5 days.
How were Lincoln Pharmaceuticals Ltd’s earnings last quarter?
Lincoln Pharmaceuticals Ltd released its earnings results on Feb 12, 2026. The company reported ₹14.279 earnings per share for the quarter, beating the consensus estimate of N/A by ₹14.279.
Is Lincoln Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Lincoln Pharmaceuticals Ltd’s price is currently Overvalued.
Does Lincoln Pharmaceuticals Ltd pay dividends?
Lincoln Pharmaceuticals Ltd pays a Annually dividend of ₹1.8 which represents an annual dividend yield of 0.37%. See more information on Lincoln Pharmaceuticals Ltd dividends here
What is Lincoln Pharmaceuticals Ltd’s EPS estimate?
Lincoln Pharmaceuticals Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lincoln Pharmaceuticals Ltd have?
Lincoln Pharmaceuticals Ltd has 20,029,728 shares outstanding.
What happened to Lincoln Pharmaceuticals Ltd’s price movement after its last earnings report?
Lincoln Pharmaceuticals Ltd reported an EPS of ₹14.279 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 15.516%.
Which hedge fund is a major shareholder of Lincoln Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in IN:LINCOLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company's product portfolio includes dermatologist preparations, gynecological products, gastrointestinal ranges, otology products, and phosphodiesterase type 5 inhibitor and general anesthetics. It provides products in the areas of cough and cold, anti-allergic, and anti-asthmatics; sterile ophthalmic eye drops and ointment; anti-malarial; vitamins, minerals, and antioxidants; anti-bacterial, anti-viral, and anti-fungal vitamins; analgesic and anti-pyretic; anti-psychotic, anti-convulsant, anti-depressant, and anti-diabetic; cardiac anti-hypertensives, and diuretic; and anti-diarrheal, anti-spasmodic, and laxative. The company also offers branded generics. Lincoln Pharmaceuticals Limited was founded in 1979 and is based in Ahmedabad, India.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Jagsonpal Pharmaceuticals Ltd.
―
Syncom Formulation (India) Ltd.
―
Venus Remedies Limited
―
Wanbury Limited
―